As shown in Fig. 2 and Table 2, the performance of anti-GNAS autoantibody was further explored in each of the HCC subgroups such as clinical stages, AFP levels, gender, age, and HBV status. This evidence concerns the gene AFP and hepatocellular carcinoma.